GlassScriptPhysician profile
Kendall Sacharczyk
NPI 1427603323
$1,522.95
in general payments reported to CMS, 2019-2025
25 companies · $647 in 2025
The $647 reported for 2025 was more than what 90% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $196 · 2024: $680 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $377.49 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Sumitomo Pharma America, INC. | $151.55 | 2023-2024 | Myfembree, Gemtesa |
| Abbvie INC. | $123.87 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $80.73 | 2024-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $79.62 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $69.33 | 2024-2025 | |
| Pfizer INC. | $64.90 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.19 | 2024 | Jardiance, Ofev |
| Lilly USA, LLC | $55.12 | 2024-2025 | Mounjaro, Kisunla, Zepbound |
| Amgen INC. | $51.43 | 2024-2025 | Repatha, Otezla, Repatha |
| Seqirus USA INC | $49.64 | 2024-2025 | Fluad, Flucelvax |
| C2n Diagnostics, LLC | $48.78 | 2025 | Precivityad2 |
| Phathom Pharmaceuticals, INC. | $44.50 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $33.60 | 2024-2025 | Quviviq, Quviviq |
| Boston Scientific Corporation | $31.87 | 2025 | Watchman Flx |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.00 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $25.09 | 2024 | Rexulti |
| Ardelyx, INC. | $24.20 | 2024 | Ibsrela |
| Hologic Sales and Service, LLC | $24.05 | 2023 | Omni Hysteroscope |
| Kowa Pharmaceuticals America, INC. | $18.89 | 2024 | Zoryve |
| Janssen Pharmaceuticals, INC | $18.22 | 2024 | Spravato |
| Ascensia Diabetes Care US INC. | $17.45 | 2025 | |
| Shield Therapeutics INC | $15.58 | 2023 | Accrufer |
| Esperion Therapeutics, INC. | $15.22 | 2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.63 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Sacharczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.